Boston Scientific (NYSE:BSX) Stock Rating Lowered by TD Cowen

Key Points

• TD Cowen downgraded Boston Scientific from “buy” to “hold” and set a $46 price target, implying approximately 7.8% upside from the $42.69 share price.
• Several analysts recently lowered their price targets, although the consensus remains a “Moderate Buy” with an average target of $61.53.
• Boston Scientific’s latest results met EPS expectations and exceeded revenue estimates, but its outlook faces pressure from a cybersecurity outage, weaker near-term growth and reduced full-year earnings guidance.

Boston Scientific (NYSE:BSX - Get Free Report) was downgraded by research analysts at TD Cowen from a "buy" rating to a "hold" rating in a research report issued on Friday, Marketbeat reports. They currently have a $46.00 target price on the medical equipment provider's stock. TD Cowen's target price points to a potential upside of 7.76% from the company's current price.

BSX has been the subject of several other reports. BTIG Research lowered their price objective on Boston Scientific from $56.00 to $49.00 and set a "buy" rating for the company in a research report on Thursday. Citigroup cut their target price on Boston Scientific from $48.00 to $44.00 and set a "neutral" rating on the stock in a research report on Thursday. Argus cut Boston Scientific from a "buy" rating to a "hold" rating in a research note on Friday, July 31st. Royal Bank Of Canada decreased their target price on Boston Scientific from $70.00 to $52.00 and set an "outperform" rating for the company in a research note on Thursday. Finally, Canaccord Genuity Group lowered their price target on Boston Scientific from $66.00 to $48.00 and set a "buy" rating for the company in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Boston Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $61.53.

Boston Scientific Price Performance

Shares of BSX opened at $42.69 on Friday. Boston Scientific has a twelve month low of $39.57 and a twelve month high of $105.65. The firm's fifty day simple moving average is $44.93 and its 200-day simple moving average is $57.15. The firm has a market capitalization of $61.86 billion, a price-to-earnings ratio of 18.09, a PEG ratio of 1.04 and a beta of 0.58. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting analysts' consensus estimates of $0.73. The firm had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The company's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.75 earnings per share. Equities analysts forecast that Boston Scientific will post 3.18 EPS for the current fiscal year.

Insider Activity

In other news, CEO Michael Mahoney bought 186,240 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David Habiger bought 2,100 shares of the business's stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director directly owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 189,522 shares of company stock worth $9,157,810. Corporate insiders own 0.34% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BSX. Integrity Alliance LLC. boosted its holdings in Boston Scientific by 20.9% in the 3rd quarter. Integrity Alliance LLC. now owns 7,525 shares of the medical equipment provider's stock valued at $328,000 after purchasing an additional 1,301 shares in the last quarter. First Nebraska Trust Co purchased a new position in shares of Boston Scientific during the 3rd quarter worth approximately $4,847,000. Factory Mutual Insurance Co. raised its stake in shares of Boston Scientific by 227.0% during the 3rd quarter. Factory Mutual Insurance Co. now owns 276,600 shares of the medical equipment provider's stock worth $12,074,000 after buying an additional 192,000 shares in the last quarter. Legacy Wealth Management LLC MS lifted its holdings in shares of Boston Scientific by 17.0% in the 3rd quarter. Legacy Wealth Management LLC MS now owns 49,998 shares of the medical equipment provider's stock valued at $2,182,000 after buying an additional 7,250 shares during the period. Finally, Signature Equity Partners LLC lifted its holdings in shares of Boston Scientific by 80.1% in the 3rd quarter. Signature Equity Partners LLC now owns 1,156 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 514 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter revenue of approximately $5.14 billion, ahead of consensus estimates, while adjusted EPS of $0.73 matched expectations. The results extended the company’s record of solid quarterly execution, although year-over-year EPS declined from $0.75. Boston Scientific Q3 Earnings Match Estimates
• Positive Sentiment: Some analysts continue to see long-term value. BTIG, Needham, UBS and Baird retained positive ratings, while Baird raised its target to $51. However, Needham, UBS and BTIG all reduced their targets, reflecting more cautious assumptions. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Management remains confident in Boston Scientific’s long-term strategy and expects a potential growth trough in 2027 followed by expansion toward 2030. That longer-term narrative is being weighed against substantial near-term execution risks. Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance
• Negative Sentiment: The cybersecurity outage lasted about eight days and reduced third-quarter sales by roughly $150 million. The disruption continues to affect operations, customer activity and the recovery timeline. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Boston Scientific cut its full-year 2026 adjusted EPS outlook to $3.16–$3.18, below investor expectations, and forecast fourth-quarter EPS of $0.77–$0.79. Fourth-quarter sales could decline year over year, intensifying concerns about weaker momentum. Boston Scientific Cuts View Again After Cyberattack
• Negative Sentiment: Analysts have become more cautious: JPMorgan downgraded BSX from overweight to neutral with a $46 target, Oppenheimer moved from outperform to market perform, and Wells Fargo lowered its target to $45. Concerns include weakness in electrophysiology and WATCHMAN products, China pricing pressure and potentially flat growth in 2027. Boston Scientific Stock Gets Downgrade from JPMorgan

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.